Splenectomy for hematological disorders by Jankulovski, Nikola et al.
PRILOZI, Odd. med. nauki, XXXV 1, 2014                                                                                                                 MANU 






SPLENECTOMY FOR HAEMATOLOGICAL DISORDERS 
 
Nikola Jankulovski¹, Svetozar Antovic¹, Biljana Kuzmanovska², Aleksandar Mitevski³ 
 
1 University Clinic for Digestive Surgery, Skopje, R. Macedonia 
2 CARIC (Clinic for Anesthesiology Reanimation and Intensive Care), Skopje, R. Macedonia 
3 Clinical Hospital Stip, R. Macedonia  
 
Corresponding Author: Nikola Jankulovski, University Clinic for Digestive Surgery, Skopje, R. Macedonia,  




Splenectomy is therapeutic for a large host of conditions. It is a consequence of expanding the list of 
disorders and liberalizing the indications for splenectomy in many diseases. Red blood cells disor-
ders: autoimmune hemolytic anemia, hereditary spherocytosis, hemoglobinopathies and thalassemia 
are prone to splenectomy after failure of medical therapy. A variety of thrombocytopenic disorders 
are improved by splenectomy, and the most common indication for splenectomy is ITP (idiopathic 
thrombocytopenic purpura). Splenectomy is successful in reversing hypersplenism in a spectrum of 
disease called myeloproliferative disorders. Relief of symptoms from splenomegaly is also achieved, 
but it does not affect the inexorable course of the disorder. The role of splenectomy in white blood 
cells disorders (leukemias and lymphomas) is only palliative and facilitates chemotherapy. 
Splenectomy in patients with hemathologic disorders imparts a risk of fulminant and life threatening 
infection "overwhelming postsplenectomy sepsis" that can be obviated by appropriate treatment.  
Although splenectomy for hemathologic disorders is only therapeutic and not curative, the relief of 
symptoms and for some disorders facilitation of chemotherapy leads to better quality of life and 
longer survival. 
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Galen’s "organum plenum misterii", the 
spleen is an organ localized in left hypochod-
rium relative to the 9th, 10th and 11th rib. The 
normal length of the spleen is 7–11 cm [1]. It 
has many functions that can be divided in two 
large groups haematologic and immune. These 
two functions are close related to the physio-
logy and pathophysiolgy of the spleen [2]. 
Splenectomy has important role in the trea-
tment of haematological disorders, although it 
has only therapeutic and no curative intent the 
list of indications for splenectomy is expanding 
[3]. 
 
Indications for splenectomy  
in haematological disorders 
Splenectomy is therapeutic for a large 
host of conditions. Haematological disorders 
can be divided into the following broad catego-
ries: red blood cell disorders and hemoglobino-
pathies, white blood cell disorders, platelet 
disorders, bone marrow disorders (myeloproli-
ferative disorders) [2] Table 1. 
Red blood cell disorders 
Hereditary spherocytosis (HS) is the most 
common haemolytic anaemia in North Euro-
peans. It is autosomal dominant and it results 
with shortened RBC life by retention and damage 
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of abnormal red cells, caused by an intrinsic 
erythrocyte membrane defect. Splenomegaly is 




Operative indications for splenectomy  
in haematological disorders 
Disease Splenectomy 
requred 
Hereditary spherocytosis Always 
Hereditary eliptocytosis Sometimes 
Thalassemia Sometimes 
Sickle cell anaemia Rarely 
Autoimmune haemolytic anaemia Usually 
Autoimmune neutropenia Sometimes 





Hairy cell leukaemia Rarely 
Chronic lymphocytic leukaemia Sometimes 
Chronic myelogenous leukaemia Sometimes 
Non-Hodgkin lymphoma Sometimes 
Agnogenic myeloid metaplasia Sometimes 
Mastocytosis Rarely 
Hodgkin disease Rarely 
 
Autoimmune Haemolytic Anaemia (AIHA) 
is a result of autoantibodies against antigens on 
red blood cells. Anaemia, splenomegaly, reti-
culocytosis, and elevated products of red blood 
cell destruction are found [6, 7]. 
Haemoglobinopathies: thalassemia and 
sickle cell disease are genetic disorders related 
to defect in haemoglobin synthesis. Anaemia 
and splenomegaly are present [8, 9, 10]. 
Bone marrow disorders  
(myeloproliferative disorders) 
Characterized by an abnormal growth of 
early cell lines in the bone marrow. Sympto-
matic splenomegaly, hypersplenism early sa-
tiety, poor gastric emptying, heaviness or pain 
in the left upper quadrant, and even diarrhoea 
can be present [11, 12].  
White blood cell disorders 
Leukemias  
Chronic Lymphocytic Leukemia (CLL) is 
a result progressive accumulation of long-lived 
but non-functional monoclonal lymphocytes. 
Most frequent finding is lymphadenopathy, 
splenomegaly and cytopenias. Hairy Cell Leu-
kemia (HCL), characterized by splenomegaly, 
pancytopenia, and large numbers of abnormal 
lymphocytes in the bone marrow [2].  
Lymphomas 
Non-Hodgkin's Lymphoma (NHL) is a 
group of malignancies derived from the lym-
phoid system. A proliferation of any one of the 
three predominant lymph cell types – natural 
killer cells, T cells, or B cells – may be inclu-
ded in NHL. Sub-entities of NHL may be cli-
nically classified into nodal or extranodal, sple-
nomegaly exists in various, but not all, forms 
of NHL. It presents the most common primary 
and secondary malignancy of the spleen. Pri-
mary-splenic involvement is considered when 
the disease may also extend to the bone 
marrow (BM), peripheral blood (PB), and/or 
the liver, in the absence of prominent lymph 
node involvement [13, 14, 15]. 
Hodgkin's Disease (HD) is a disorder of 
the lymphoid system characterized by the pre-
sence of Reed-Sternberg cells. More than 90% 
of patients with HD present with lymphadeno-
pathy above the diaphragm. Lymph nodes can 
become particularly bulky in the mediastinum, 
which may result in shortness of breath, cough, 
or obstructive pneumonia. Lymphadenopathy 
below the diaphragm is rare on presentation but 
can arise with disease progression. The spleen 
is often an occult site of spread, but massive 
splenomegaly is not common. In addition, large 
spleens do not necessarily signify involvement. 
Staging procedure for HD begins with a wedge 
biopsy of the liver, splenectomy, and the 
removal of representative nodes in the retrope-
ritoneum, mesentery, and hepatoduodenal liga-
ment. Staging for HD may be performed lapa-
roscopically and it is indicated in Stage Ia-IIa 
patients where results may affect medical ma-
nagement (radiation vs chemotherapy) [2, 16, 17]. 
Platelet disorders 
Thrombotic Thrombocytopenic Purpura 
(TTP) is associated with large multimers of 
Von Willebrand factor causing platelet clum-
ping. Thrombocytopenia, microangiopathic hae-
molytic anaemia, and neurologic complications 
are present [2]. 
Idiopathic Thrombocytopenic Purpura (ITP) 
is a result of autoantibodies directed against 
platelet surface antigens. Highest incidence is 
in women aged 15–50. Usually idiopathic but it 
may be seen in conjunction with: SLE, HIV, 
CLL, Hodgkin’s Dz, or autoimmune haemo-
lytic anaemia. Normal platelet lifespan is de-
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creased from 7–10 days to 5 hrs (or total pla-
telet turnover 5 × normal).  It may remit and re-
lapse over time and medical treatment is suc-
cessful in only about 15% of patients Splene-
ctomy is successful in 66% of patients initially, 
with full response. Additional 15% with partial 
response, 15% of these will relapse with 1 year. 
Indications for Splenectomy in ITP: Persistent 
platelet count < 80,000/mm3 despite therapy; 
Recurrence of thrombocytopenia after tapering 
or discontinuation of steroids; Children: indica-
ted if there is no remission after 1 year of 
medical treatment [18, 19, 20, 21].  
 
Splenomegaly and Hypersplenism 
There is not a single universally accepted 
standard, but most would agree that an ex vivo 
mass of > 1 kg or a pole-to-pole length of > 15 
cm generally qualifies as splenomegaly [2]. 
Hypersplenism on the other hand represents 
"Haematological effects of splenomegaly" and 
results in enhanced capacity of the enlarged 
spleen: pooling, sequestering and destroying 
blood cells. Thus hypersplenism is the presence 
of one or more cytopenias in the context of a 
normally functioning bone marrow. Disorders 
causing hypersplenism can be categorized as 
either (a) those in which increased destruction 
of abnormal blood cells occurs in an intrinsi-
cally normal spleen (e.g., hemolytic anemias) 
or (b) primary disorders of the spleen resulting 
in increased sequestration and destruction of 
normal blood cells (e.g., infiltrative disorders) 




Causes of hypersplenism in haematological disorders 
Primary disease of blood 
cells (normal spleen) Primary disorder of the spleen
Congenital Neoplastic 
Erythrocyte abnormality Hairy cell leukaemia 
Hereditary spherocytosis Chronic lymphocytic leukaemia 
Hereditary elyptocytosis Chronic myelogenus leukaemia 
Piruvate kinase deficiency Non-Hodgkin lymphoma 
Haemoglobin abnormality Cellular infiltration (haematopoesis) 
Thalessemia major Agnogenic myeloid metaplasia  












Why splenectomy in hypersplenism?  
• Treat Splenomegaly (Compressive symp-
toms, risk for splenic injury if active); 
• Improve blood counts – RBC’s, Platelets; 
• Temporize underlying condition (reduce 
number of required transfusions, failed me-
dical management or facilitation of chemo-
therapy, pain or abcess secondary to sple-
nic infarction.); 
• Staging Procedure. 
 
Open or laparoscopic splenectomy? 
Firs recorded splenectomy dates from 1549 
and was performed by Andirano Zaccarello. 
Traditionaly it was done by an open approach 
using medial or left sub costal incision. Lapa-
roscopic splenectomy was first reported by De-
laitre and Maignien in 1991 [23]. It is now 
accepted that laparoscopic splenectomy  is safe 
and advantageous procedure in experienced 
hands that has displaced open surgery for al-
most all indications [25). Many studies show 
that laparoscopic splenectomy is indicated and 
safe in all benign and malignant haematolo-
gical diseases [26, 27] and contraindications do 
not differ from that of open splenectomy [28, 
29]. Contraindications include the inability to 
tolerate general anesthesia, uncontrollable coa-
gulopathy, and the need for laparotomy for 
associated procedures. Difference is found in 
massive, large spleens where morbidity and 
conversion rates to open are higher [30, 31] but 
implementation of hand-assisted technique re-
duced them (Table 3). Laparoscopic spleen-
ctomy is also associated with shorter hospital 
stay in all haematological disorders. Compli-
cations related to laparoscopic splenectomy are 
similar to open splenectomy or other major ab-
dominal procedures. They include intraopera-
tive and postoperative hemorrhage; infections 
including wound infection, pneumonia, and 
overwhelming postsplenectomy sepsis (OPSS). 
Injury to other structures such as the colon, 
stomach or most notably, the pancreatic tail, 
which can cause pancreatic abscesses or fis-
tulas. Other complications specifically associa-
ted with laparoscopic and open splenectomy 
include the risk of missed accessory spleens 
and portal vein thrombosis [23].  
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Table 3 
 
Classification of spleens according to spleen length 
(spleen length is measured along strait line between  
two poles) 
 
Spleen class Spleen lenght 
Normal spleen 7–11 cm 
Moderate splenomegaly 12–20 cm 
Massive splenomegaly 21–30 cm 
Megaspleen > 30 cm 
 
Laparoscopic splenectomy  
Most LS (laparoscopic splenectomy) pro-
cedures are now performed with the patient in 
the right lateral decubitus position (Figure 1 
and 2). A midway "double-access" technique in 
which the patient is in a 45-degree right lateral 
decubitus position has also been advocated. 
The double-access technique requires the pla-
cement of five or six trocars. The lateral ap-
proach routinely involves the use of three or 
four trocars. Use of an angled (30- or 45-degree) 
laparoscope (2 mm, 5 mm, or 10 mm) greatly 
facilitates the procedure. Exposure of the vital 
anatomy in a manner that allows for a more 
intuitive sequence of dissection, paralleling that 
of OS, may be considered an additional advan-
tage of the lateral approach (Figure 3). Place-
ment of trocars in the left upper quadrant 
should be performed under laparoscopic visua-
lization, particularly if any degree of splenome-
galy exists, because the latter can significantly 
reduce the available operating space. As with 
OS, the splenocolic ligament and the lateral pe-
ritoneal attachments are divided with resultant 
medial mobilization of the spleen. The short 
gastric vessels may be divided by any number 
of methods, including individual application of 
clips, endovascular stapling, or, most com-
monly, use of hemostatic energy sources as in 
ultrasonic dissection, diathermy or bipolar com-
pression coagulation. With the lower pole of 
the spleen gently retracted, the splenic hilum is 
accessible to further applications of clips or an 
endovascular stapling device. The splenic ar-
tery and vein are divided separately when pos-
sible. Good long-term outcomes, however, are 
increasingly being achieved with mass hilar 
stapling. Using the lateral approach with the 
spleen thus elevated, the surgeon can easily vi-
sualize the tail of the pancreas and avoid injury 
when placing the endovascular stapler. Once 
excised, the spleen is placed in a durable rip-
stop nylon sack, the neck of which is drawn 
through one of the 10-mm trocar sites. Morce-
llation of the spleen takes place within the sack 
and allows piecemeal extraction; a blunt instru-
ment should be used to disrupt and remove the 
spleen to avoid the risk of sack rupture, spillage 
of contents, and subsequent splenosis [2, 23]. 
 
Figure 1 – Right lateral decubitus position  
and trocar positioning 
 
Figure 2 – Right lateral decubitus position  
and trocar positioning 
 
Figure 3 – Vital anatomy exposure of the spleen 
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Overwhelming Post-Splenectomy 
Sepsis 
OPSS is rear but usually fatal compli-
cation, it has mortality rate of 50–60% even 
when treated [32, 33]. Occurs more often in 
immunocompromised adults and in children. 
80% of cases are in first two years following 
splenectomy. It is caused mainly by encapsu-
lated bacteria: Streptococcus pneumoniae, Nei-
sseria meningitidis and Haemophilus influen-
zae, other bacteria like Escherichia coli, Strep-
tococcus b-hemolytic, Staphylococcus aureus 
and Pseudomonas sp. represent a significant 
risk as well [34]. Appropriate precautions and 
preventive measures are of importance, four 
measures consist the guidelines for prevention 
and treatment of OPSS: 1. vaccination with 
polyvalent pneumococcal vaccine 10–14 days 
prior elective splenectomy; 2. high risk patients 
(children and immunocompromised) should 
also receive vaccine against Haemophilus and 
Neisseria; 3. antibiotic prophylaxis (especially 
high risk patients); 4. early antibiotic treatment 




Guidelines  for prevention and treatment of OPSS 
 
 Guidelines  for prevention and treatment of OPSS
1 Vaccination with polyvalent pneumococcal 
vaccine 10–14 days prior elective splenectomy 
2 High risk patients (children and immunocompro-
mised) should also receive vaccine against 
Haemophilus and Neisseria 
3 Antibiotic prophylaxis (especially high risk 
patients) 
4 Early antibiotic treatment in signs of infection 
 
University Clinic for Digestive 
surgery -Skopje experience 
Laparoscopic splenectomy (LS) was in-
troduced I 2005 in our clinic. During 5 year 
period 2005–2010, 40 LS were performed for 
haematological disorders, other indications (tra-
uma, malignant disease, other) included only 3 
LS. Open splenectomy (OS) was analyzed in 
the period 2000–2010 and 21 OS were per-
formed for haematological disorders in the 
period 2005–2010 and only 16 in the period 
2000–2005, all together 37 OS in 10 years 
period. Main duration of surgery for LS was 
166min and main hospitalization 6.8 days and 
blood transfusion 26 ml, Table 5 and 6. 
Table 5 
 
Patients undergoing splenectomy in the period  
2000–2010 




















Comparison between laparoscopic and open surgery  
in patients with haematological disease (2000–2010) 
 Laparoscopic 
splenectomy 
n = 40 
Open 
splenectomy 




166.1 ± 54.9 
 




6.87 ± 2.2 
 




26.2 ± 93.4 
 
132.4 ± 252.3 
 
Conclusion  
Splenectomy for haematological disorders 
is only therapeutic and not curative, the relief of 
symptoms and for some disorders facilitation of 
chemotherapy  leads to better quality of life and 
longer survival. Laparoscopic splenectomy is a 
procedure of choice when performed for haema-
tological disorders and together with new ima-
gine techniques decreased the need for dia-
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Спленектомијата претставува терапевтска 
метода за многу различни состојби. Причина за 
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тоа е либерализација на индикацијата и проши-
рување на листата на болести подложни на 
спленектомија. Нарушувањата на црвената крвна 
лоза: автоимуна хемолитичка анемија, хереди-
тарна свероцитоза, хемоглобинопатии и таласе-
мија се болести кај кои се применува спленек-
томија по неуспешна медикаментозна терапија. 
Значително подобрување на тромбоцитопенија 
има кај најголем број тромбоцитопении по спле-
нектомија, а најчеста индикација за спленекто-
мија претставува ИТП (идиопатска тромбоцито-
пениска пурпура). Спленектомијата успешно го 
третира хиперспленизмот кај миелопролифера-
тивните болести, се постигнува и намалување на 
симптомите од самата спленомегалија, но без 
ефект на неповратниот тек на болеста. Во боле-
стите на белата крвна лоза (леукемија и лим-
фоми) спленектомијата има само палијативна 
улога, овозможува да се воведе хемотерапија. 
Кај пациентите со хематолошки заболу-
вања спленектомијата носи зголемен ризик од 
појавување на фулминантната и животозагрозу-
вачка постспленектомиска сепса. 
Иако спленектомијата кај хематолошките 
болести има само терапевтска, но не и кура-
тивна улога, намалувањето на симптомите кај 
некои нарушувања и воведувањето хемотера-
пија кај други доведува до подобар квалитет на 
животот и подолго преживување. 
 
Клучни зборови: спленектомија, лапароскопска спле-
нектомија, хематолошки заболувања, хередитарна 
сфероцитоза, идиопатска тромбоцитопениска пур-
пура, ИТП, миелопролиферативни болести, лимфом, 
постспленектомиска сепса. 
 
 
 
 
 
 
 
 
 
 
 
